Business Model
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development.
 
Nimotuzumab
Anti-cancer antibody that targets the epidermal growth factor receptor, with an improved side-effect profile compared to marketed EGFR-targeting products
AeroLEF®
Proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl
CYT387
Novel JAK1/JAK2 inhibitor for multiple indications including MPNs
CYT997
Novel anti-cancer Vascular Disrupting Agent (VDA)
 
   
consortium
 
science
dosing
 
science
 
clinical trials
 
safety profile
clinical trials
news
events
webcasts

 

March 16, 2010
10:30 AM (PST)
22nd Annual ROTH Orange County Growth Stock Conference The Rtiz-Carlton Laguna Niguel, Track 8
Dana Point, CA
Presenter: David Allan
listen to webcast

November 19, 2009
4:00 PM (EST)
YM BioSciences Annual General Meeting
of Shareholders
TSX Broadcast Centre Gallery
The Exchange Tower
130 King Street W., Toronto, Ontario
listen to archived webcast | view AGM presentation

presentations
reports
posters & publications

Corporate Presentation
Calendar First Quarter 2010

Nimotuzumab Proposed Mechanism of Action

The AeroLEF Concept

2009 Annual Report

U.S. Senate Report on Changing Cuba Policy


 

Combination treatment with metronomic cyclophosphamide and the EGFR monoclonal antibody nimotuzumab is efficacious and non-toxic in a preclinical model of advanced triple negative breast cancer. Lead author: Anthony J. Mutsaers, Sunnybrook Health Sciences Centre (2009 AACR Molecular Targets and Cancer Therapeutics)

ASCO 2009 poster presentation reporting results from a randomized trial of nimotuzumab (aka BIOMab/TheraCIM/h-R3) in patients with head & neck cancer. Conducted by Biocon Limited (Bangalore, India), a licensee of CIMAB SA, YM's licensor.


Binding properties of the anti-EGFR monoclonal antibody, nimotuzumab, limit interaction with the EGFR in renal and epidermal cells (2009 AACR Annual Meeting)